Vectors and methods for gene transfer to cells

• US 5,965,541 A
• Filed: 11/28/1995
• Issued: 10/12/1999
• Est. Priority Date: 11/28/1995
• Status: Expired due to Term

• Current Assignee: GenVec, Inc. (Precigen, Inc.)
• Original Assignee: GenVec, Inc. (Precigen, Inc.)
• Inventors: Brough, Douglas E., Kovesdi, Imre, Wickham, Thomas J.
• Primary Examiner(s): Ketter, James
• Assistant Examiner(s): Yucel, Irem
• Application Number:
  US08/563,368
• Time in Patent Office: 1,414 Days
• Field of Search: 435/320.1, 435/69.7, 435/172.1, 435/172.3, 435/69.1, 435/367, 435/369, 435/370, 435/456, 536/24.2, 536/23.4, 536/23.72, 935/22, 935/23, 935/32, 935/57, 514/44, 530/350
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/10345 Special targeting system for viral vectors
• CPC Class Codes: C12N 2810/40 Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
• CPC Class Codes: C12N 2810/405 Vectors comprising RGD peptide
• CPC Class Codes: C12N 2810/60 from viruses
• CPC Class Codes: C12N 2810/6018 Adenoviridae

Abstract

The present invention provides a chimeric adenovirus coat protein, which differs from the wild-type coat protein by the introduction of a nonnative amino acid sequence. Such a chimeric adenovirus coat protein according to the invention is able to direct entry into cells of a vector comprising the coat protein that is more efficient than entry into cells of a vector that is identical except for comprising a wild-type adenovirus coat protein rather than the chimeric adenovirus coat protein. The chimeric coat protein preferably is a fiber, hexon, or penton protein. The present invention also provides an adenoviral vector that comprises the chimeric adenovirus coat protein, as well as methods of constructing and using such a vector.

Claims

1. A chimeric adenovirus coat protein comprising a nonnative amino acid sequence, wherein said chimeric adenovirus coat protein directs entry into cells of a vector comprising said chimeric adenovirus coat protein that is more efficient than entry into cells of a vector that is identical except for comprising a wild-type adenovirus coat protein rather than said chimeric adenovirus protein, and wherein said chimeric adenovirus coat protein binds a novel endogenous binding site present on the cell surface.

2. The chimeric adenovirus coat protein of claim 1, wherein said nonnative amino acid sequence is inserted into or in place of an internal coat protein sequence.

3. The chimeric adenovirus coat protein of claim 1, wherein said nonnative amino acid sequence is at or near the C-terminus of said protein.

4. The chimeric adenovirus coat protein of claim 1, wherein said nonnative amino acid sequence is linked to said protein by a spacer sequence of from about 3 to about 30 amino acids.

5. The chimeric adenovirus coat protein of claim 1, wherein said nonnative amino acid sequence comprises from about 3 to about 30 amino acids.

6. The chimeric adenovirus coat protein of claim 5, wherein said nonnative amino acid sequence comprises amino acids selected from the group consisting of lysine, arginine, and histidine.

7. The chimeric adenovirus coat protein of claim 5, wherein said nonnative amino acid sequence comprises amino acids selected from the group consisting of aspartate and glutamate.

8. The chimeric adenovirus coat protein of claim 5, wherein said nonnative amino acid sequence comprises a sequence selected from the group consisting of SEQ ID NO:

1, SEQ ID NO;

2, and SEQ ID NO;

3, and wherein said sequence may be deleted at the C-terminus by 1, 2, 3, 4, or 5 residues.

9. The chimeric adenovirus coat protein of claim 8, wherein said chimeric adenovirus coat protein is a chimeric adenovirus hexon protein or a chimeric adenovirus penton protein.

11. The chimeric adenovirus coat protein of claim 1, wherein said chimeric adenovirus coat protein forms homotrimers in aqueous solutions.

12. The chimeric adenovirus coat protein of claim 1, wherein said chimeric adenovirus coat protein can fold to allow the coat protein to be incorporated into an adenovirus.

13. The chimeric adenovirus coat protein of claim 1, wherein said chimeric adenovirus coat protein is a fiber protein.

14. The chimeric adenovirus coat protein of claim 13, wherein said fiber protein comprises a sequence selected from the group consisting of SEQ ID NO:

1, SEQ ID NO;

2, and SEQ ID NO;

3, and wherein said sequence may be deleted at the C-terminus by 1, 2, 3, 4, or 5 residues.

15. The chimeric adenovirus coat protein of claim 1, wherein said chimeric adenovirus coat protein is a penton protein or a hexon protein.

16. An isolated and purified nucleic acid encoding a chimeric adenovirus coat protein of claim 1, wherein the nucleic acid sequence that encodes said nonnative amino acid sequence comprises SEQ ID NO:

6 located prior to the polyadenylation site.

17. The nucleic acid of claim 16, wherein said chimeric adenovirus coat protein is a fiber protein.

18. The nucleic acid of claim 16, wherein said chimeric adenovirus coat protein is a penton protein or a hexon protein.

20. The vector that comprises or encodes the chimeric adenovirus coat protein of claim 1.

21. The vector of claim 20, wherein said vector is a viral vector selected from the group consisting of nonenveloped viruses.

22. The vector of claim 20, wherein said vector is an adenoviral vector.

23. The vector of claim 22, wherein said vector further comprises a nucleic acid comprising a passenger gene.

24. The vector of claim 23, wherein said nucleic acid is inserted into the adenoviral genome.

25. The vector of claim 22, wherein said chimeric adenovirus coat protein is a fiber protein.

26. The vector of claim 25, wherein said fiber protein comprises a sequence selected from the group consisting of SEQ ID NO:

1, SEQ ID NO;

2, and SEQ ID NO;

3, and wherein said sequence may be deleted at the C-terminus by 1, 2, 3, 4, or 5 residues.

27. The vector of claim 22, wherein said chimeric adenovirus coat protein is a penton protein, and said vector does not comprise wild-type fiber protein.

29. An isolated cell comprising the vector of claim 20.

30. The vector of claim 20, wherein said vector can be propagated in vitro in 293 cells.

32. A transfer vector that encodes the chimeric adenovirus coat protein of claim 1.

33. The transfer vector of claim 32, wherein said transfer vector is selected from the group consisting of nonenveloped viruses.

34. The transfer vector of claim 32, wherein said transfer vector is an adenoviral vector.

35. The transfer vector of claim 32, wherein said transfer vector further comprises a nucleic acid encoding a passenger gene.

36. The transfer vector of claim 32, wherein said coat protein is a fiber protein.

37. The transfer vector of claim 36, wherein said fiber protein comprises a sequence selected from the group consisting of SEQ ID NO:

6, SEQ ID NO;

7, and SEQ ID NO;

8, and conservatively modified variants thereof.

38. The transfer vector of claim 32, wherein said chimeric coat protein is a chimeric adenovirus hexon protein or a chimeric adenovirus penton protein.

41. A method of increasing the efficiency of entry into a cell of a viral vector comprising a coat protein, which method comprises:

(i) replacing a coat protein of said viral vector with the chimeric adenovirus coat protein of claim 1, and

(ii) contacting a cell with said viral vector in vitro, such that said vector enters said cell more efficiently than an otherwise identical vector comprising a wild-type adenovirus coat protein.

42. The method of claim 41, wherein said vector is an adenoviral vector that further comprises a nucleic acid comprising a passenger gene.

43. The method of claim 42, wherein said nucleic acid is inserted into the adenoviral genome.

44. A method of increasing the efficiency of introduction of a nucleic acid into a cell, which method comprises;

(a) obtaining a vector comprising the chimeric adenovirus coat protein of claim 5,

(b) contacting said viral vector with a nucleic acid comprising a passenger gene such that said chimeric adenovirus coat protein and said nucleic acid bind by a protein/DNA interaction, and

(c) contacting a cell with said viral vector to which is bound said nucleic acid in vitro, such that said nucleic acid enters said cell more efficiently than an identical nucleic acid contacted with an otherwise identical viral vector comprising a wild-type adenovirus coat protein.

45. A method of making the chimeric adenovirus coat protein of claim 1, comprising introducing a spacer sequence into the coding sequence of said chimeric adenovirus coat protein prior to any stop codon or polyadenylation signal.

46. The method of claim 45, wherein said spacer sequence comprises the sequence of SEQ ID NO:

6 or a conservatively modified variant thereof.

48. A method of increasing the efficiency of entry into a cell of a vector comprising a coat protein, which method comprises:

(i) obtaining a viral vector comprising the chimeric adenovirus coat protein of claim 1 and a nucleic acid comprising a passenger gene, and

(ii) contacting a cell with said vector in vitro, such that said vector enters said cell more efficiently than an otherwise identical vector comprising a wild-type adenovirus coat protein.

49. The method of claim 48, wherein said nucleic acid is inserted into the viral genome.

50. A method of increasing the efficiency of introduction of a nucleic acid into a cell, which method comprises:

(i) obtaining a viral vector comprising the chimeric adenovirus coat protein of claim 1 and a nucleic acid comprising a passenger gene, wherein said nucleic acid is bound to said chimeric adenovirus coat protein by means of a protein/DNA interaction, and

(ii) contacting a cell with said vector in vitro, such that said nucleic acid enters said cell more efficiently than an identical nucleic acid contacted with an otherwise identical vector comprising a wild-type adenovirus coat protein.

51. In a method of gene therapy comprising the administration to a patient in need of gene therapy a therapeutically effective amount of a viral vector comprising a therapeutic gene that is expressed in said patient, the improvement comprising administering to the patient said viral vector in which a coat protein has been replaced with the chimeric adenovirus coat protein of claim 1.

52. The method of claim 51, wherein said viral vector is an adenoviral vector.

53. The method of claim 51, wherein said therapeutic gene is inserted into the viral vector genome.

54. The method of claim 51, wherein said therapeutic gene is bound to the chimeric adenovirus coat protein by a protein/DNA interaction.

55. In a method of ex vivo gene therapy comprising the administration to a patient in need of ex vivo gene therapy a therapeutically effective amount of transduced cells comprising a viral vector comprising a therapeutic gene that is expressed in said cells, the improvement comprising administering to the patient said transduced cells comprising the viral vector in which a coat protein has been replaced with the chimeric coat protein of claim 1, whereupon said administration, said therapeutic gene is expressed in said patient.

56. The method of claim 55, wherein said viral vector is an adenoviral vector.

57. The method of claim 55, wherein said therapeutic gene is inserted into the viral vector genome.

58. The method of claim 55, wherein said therapeutic gene is bound to the chimeric adenovirus coat protein by a protein/DNA interaction.

59. In a method of gene therapy comprising the administration to a patient in need of gene therapy a therapeutically effective amount of a viral vector comprising a therapeutic gene that is expressed in said patient, the improvement comprising administering to the patient said viral vector in which a coat protein has been replaced with the chimeric adenovirus coat protein of claim 6.

60. The method of claim 59, wherein said viral vector is an adenoviral vector.

61. In a method of ex vivo gene therapy comprising the administration to a patient in need of ex vivo gene therapy a therapeutically effective amount of transduced cells comprising a viral vector comprising a therapeutic gene that is expressed in said cells, the improvement comprising administering to the patient said transduced cells comprising the viral vector in which a coat protein has been replaced with the chimeric coat protein of claim 6, whereupon said administration, said therapeutic gene is expressed in said patient.

62. The method of claim 61, wherein said viral vector is an adenoviral vector.

10. A chimeric adenovirus fiber protein comprising a nonnative amino acid sequence, wherein said chimeric adenovirus fiber protein directs entry into cells of a vector comprising said chimeric adenovirus fiber protein that is more efficient than entry into cells of a vector that is identical except for comprising a wild-type adenovirus fiber protein rather than said chimeric adenovirus fiber protein, and wherein said fiber protein comprises a sequence selected from the group consisting of SEQ ID NO:

4 and SEQ ID NO;

5, and wherein the length of the polylysine string can vary from about 3 to about 30 residues.

19. An isolated and purified nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:

7, and SEQ ID NO;

8, and conservatively modified variants thereof.

28. The adenoviral vector GV10 UTV.

31. A vector that comprises or encodes a chimeric adenovirus coat protein comprising a nonnative amino acid sequence, wherein said chimeric adenovirus coat protein binds a novel endogenous binding site present on a cell surface and directs entry into cells of a nucleic acid attached to said chimeric adenovirus coat protein by a protein/DNA interaction more efficiently than a corresponding wild-type adenovirus coat protein.

39. A transfer vector selected from the group consisting of pAd NS 83-100 UTV and pAd BS 59-100 UTV.

40. An adenoviral vector that comprises or encodes a chimeric adenovirus fiber protein comprising a nonnative amino acid sequence, wherein said chimeric adenovirus fiber protein directs entry into cells of a vector comprising said chimeric adenovirus fiber protein that is more efficient than entry into cells of a vector that is identical except for comprising a wild-type adenovirus fiber protein rather than said chimeric adenovirus fiber protein, and wherein said fiber protein comprises a sequence selected from the group consisting of SEQ ID NO:

4 and SEQ ID NO;

5, and wherein the length of the polylysine string can vary from about 3 to about 30 residues.

47. A method of making an adenoviral vector that comprises or encodes a chimeric adenovirus fiber protein comprising a nonnative amino acid sequence, wherein said chimeric adenovirus fiber protein directs entry into cells of a vector comprising said chimeric adenovirus fiber protein that is more efficient than entry into cells of a vector that is identical except for comprising a wild-type adenovirus fiber protein rather than said chimeric adenovirus fiber protein,

wherein said method comprises providing to a cell that does not comprise any E4 complementing sequences:

(a) a linear vector comprising the chimeric fiber and a wild-type E4 gene, and (b) a linear vector that is E4^-.